Literature DB >> 3273154

The inhibitory effect of metoclopramide on plasma cholinesterase activity.

J R Kambam1, W C Parris, J J Franks, B V Sastry, R Naukam, B E Smith.   

Abstract

The in vitro effect of metoclopramide on plasma cholinesterase (PCHE) activity was studied to investigate a mechanism for metoclopramide-induced prolongation of succinylcholine action. The mean PCHE of the control samples was 0.86 +/- 0.02 unit.ml-1. PCHE activity in the presence of metoclopramide, at concentrations of 0.05, 0.10, 0.50, 1.0, 2.5 and 5.0 micrograms.ml-1, was reduced to 0.78 +/- 0.02, 0.69 +/- 0.04, 0.50 +/- 0.03, 0.39 +/- 0.02, 0.24 +/- 0.01 and 0.15 +/- 0.01 unit.ml-1, respectively. Our data demonstrated that PCHE activity was significantly depressed by metoclopramide at all concentrations studied (p less than 0.001). Our data also show that the concentration of metoclopramide required to inhibit 50 per cent of PCHE activity (I50) was 0.8 micrograms.ml-1 (2.4 x 10(-6) M). We recommend caution when succinylcholine and or ester type local anaesthetics are administered to patients who are also receiving metoclopramide, especially in high doses.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3273154     DOI: 10.1007/BF03026894

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  16 in total

1.  The inhibitory effect of chlorpromazine and chlorpromazine sulfoxide on human cholinesterases.

Authors:  E G ERDOS; N BAART; S P SHANOR; F F FOLDES
Journal:  Arch Int Pharmacodyn Ther       Date:  1958-10-01

2.  The effect of procainamide on plasma cholinesterase activity.

Authors:  J R Kambam; R J Naukam; B V Sastry
Journal:  Can J Anaesth       Date:  1987-11       Impact factor: 5.063

3.  Metoclopramide and cardiac arrhythmia.

Authors:  M Shaklai; J Pinkhas; A de Vries
Journal:  Br Med J       Date:  1974-05-18

4.  Visualisation of the small intestine by double contrast.

Authors:  M Pajewski; J Eshchar; A Manor
Journal:  Clin Radiol       Date:  1975-10       Impact factor: 2.350

5.  Hypertensive crisis in patients with phaeochromocytoma given metoclopramide.

Authors:  E Agabiti-Rosei; C L Alicandria; L Corea
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

6.  Cimetidine, metoclopramide, or placebo in the treatment of symptomatic gastroesophageal reflux.

Authors:  P Bright-Asare; M El-Bassoussi
Journal:  J Clin Gastroenterol       Date:  1980-06       Impact factor: 3.062

7.  The effect of metoclopramide on the lower oesophageal sphincter in late pregnancy.

Authors:  J G Brock-Utne; T G Dow; S Welman; G E Dimopoulos; M G Moshal
Journal:  Anaesth Intensive Care       Date:  1978-02       Impact factor: 1.669

8.  Prevention of postoperative nausea and vomiting by domperidone: A double-blind randomized study using domperidone, metoclopramide and a placebo.

Authors:  R D Cooke; D J Comyn; R W Ball
Journal:  S Afr Med J       Date:  1979-11-17

Review 9.  Metoclopramide. An updated review of its pharmacological properties and clinical use.

Authors:  R A Harrington; C W Hamilton; R N Brogden; J A Linkewich; J A Romankiewicz; R C Heel
Journal:  Drugs       Date:  1983-05       Impact factor: 9.546

10.  Metoclopramide: antipsychotic efficacy of a drug lacking potency in receptor models.

Authors:  M Stanley; A Lautin; J Rotrosen; S Gershon; D Kleinberg
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

View more
  3 in total

1.  Metoclopramide does not prolong duration of action of landiolol attenuating the hemodynamic response to induction of anesthesia and tracheal intubation.

Authors:  Satoki Inoue; Ryuichi Abe; Masahiko Kawaguchi; Hiroshi Kobayashi; Hitoshi Furuya
Journal:  J Anesth       Date:  2010-05-08       Impact factor: 2.078

2.  Metoclopramide inhibits plasma cholinesterase.

Authors:  S G Graham; A M Burgess
Journal:  Can J Anaesth       Date:  1989-11       Impact factor: 5.063

3.  The characteristics of the inhibition of serum cholinesterase by metoclopramide.

Authors:  S G Graham; A W Crossley
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.